Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus
Year: 2010
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
Institutions: University of Copenhagen, Gentofte Hospital, Hvidovre Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: sitagliptin, DPP-4 inhibitors, type 2 diabetes, peptide YY, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-2, incretins, hyperglycaemic clamp, mixed meal tolerance test, postprandial insulin secretion, metformin add-on therapy, glycemic control
Open Access status: closed
Funder: Merck
OpenAlex ID: W2134947605
